Navigation Links
Medisafe 1 Technologies Finalises Contract to Develop Prototype of the World's First Ever Medicinal Syringe-Locking Device
Date:8/31/2010

Medisafe 1 Technologies Finalises Contract to Develop Prototype of the World's First Ever... -- JERUSALEM, August 31, 2010 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Pharmaceuticals, New Products & Services Click to view news release full screen  

Medisafe 1 Technologies Finalises Contract to Develop Prototype of the World's First Ever Medicinal Syringe-Locking Device

   

US-Patented Technology Developed to Prevent Drug-Related Injuries in Hospitals

JERUSALEM, August 31, 2010 /PRNewswire-FirstCall/ -- Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company has signed a contract to begin the production of a prototype of its patented medicinal locking device technology.

The prototype will be the first ever of its kind. The design has the potential to significantly reduce preventable drug-related injuries in hospitals and in medical clinics

The contract was signed with PIA Engineering Group (Israel), which will manufacture the prototype. The prototype is expected to be completed in three months. The PIA team includes biomechanical engineers with combined experience of over 60 years, having held senior positions at Elscint and other technology companies.

The purpose of the patented device is to physically prevent medication administration errors in hospitals and in medical clinics. The device includes a syringe-locking mechanism that works in concert with a bar-code reader and database system.

The device electronically confirms whether the syringe held by a medical practitioner contains the correct medication and dosage that has been prescribed to a particular patient, before allowing that medication to be physically administered.

"Medication administration errors in hospitals cause 400,000 preventable drug-related injuries and 70,000 deaths each year," said Jacob Elhadad, Chief Executive Officer of Medisafe 1 Technologies. "The development of this patented locking-device prototype is the first step towards significantly reducing instances of such injuries."

"As the healthcare industry in the U.S. continues to mandate the usage of safer syringe technologies, including Barcoding Point of Care (BPOC) systems, Medisafe 1 Technologies are well positioned. Factoring the possibility of widespread implementation, the total potential addressable market for Medisafe's patented technologies could exceed $1 billion per year," Elhadad added.

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. Public filings may be viewed at http://www.sec.gov.

Contact: JACOB ELHADAD CEO +972-524440000 JACOB.ELHADAD10@GMAIL.COM
'/>"/>

SOURCE Medisafe
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company
2. OrthoAccel Technologies Announces Full-Market Release of AcceleDent, a New Technology to Shorten Treatment Time in Braces
3. Wound Management Technologies Expands Distribution Foot Print in Florida with the Addition of Central Medical Systems
4. Alere and AirStrip Technologies - a Powerful Collaboration Brings Innovative Remote Patient Monitoring to Obstetrical Care
5. OrthoAccel Technologies, Inc. Announces Definitive Distribution Agreements in Two Key Markets
6. MedClean Technologies Announces Second Quarter Results
7. BioStorage Technologies to Sponsor and Present Educational Workshops at Annual Biorepositories Conference
8. Acuo Technologies Bolsters Sales Team with Key Additions
9. Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care
10. Wound Management Technologies CellerateRX® Activated Collagen™ Debuts at the South African Diabetic Foot Working Group Congress in Cape Town
11. New Report - Telemedicine Market in Brazil, Russia, India, China (BRIC) - Advanced Technologies, Global Forecast by MarketsandMarkets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017 /PRNewswire/ ... announced today the partnership of their 3D body ... in healthcare IT.  The new integration will be ... on an interactive model of the human body. ... data saves clinicians time, while also increasing the ...
(Date:2/16/2017)... , Feb. 16, 2017 Absorption Systems, ... and medical devices, is pleased to announce that its ... been selected as a winner of the 2017 Executive ... Magazine and recognizes driven executives for their creative ... ethic. The awards ceremony and celebration is on March ...
(Date:2/16/2017)... (NYSE: DVA ) today announced results for the ... Net income attributable to DaVita Inc. for the quarter and ... per share and $880 million, or $4.29 per share, respectively. ... for the quarter and year ended December 31, 2016, excluding ... per share, and $789 million, or $3.85 per share, respectively. ...
Breaking Medicine Technology:
(Date:2/18/2017)... ... 17, 2017 , ... CONTACT:, Glenn Vallecillos, MD, FACS, +1 ... Dr. Glenn Vallecillos experiments SculpSure, the hot, new, aesthetic, non-surgical procedure ... been centered around that idea that to achieve ones desired results a surgical ...
(Date:2/17/2017)... ... 17, 2017 , ... Smiles by Seese is a comprehensive family dental ... Seese leads the practice as a skilled and highly credentialed dentist who is qualified ... serves patients of all ages with excellence in general, restorative, and cosmetic dentistry ...
(Date:2/17/2017)... ... 17, 2017 , ... For the first time, International Scholarship ... exhibit floor for the 2017 HIMSS Conference & Exhibition at the ... more than 40,000 healthcare industry professionals are expected at the conference, where they ...
(Date:2/17/2017)... ... February 17, 2017 , ... Qualis Health, one ... in the 8th Annual DecisionHealth Platinum Awards in recognition of its innovative healthcare ... is recognized across multiple award categories, highlighting four of the organization’s current programs:, ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... executives and focusing on all facets of clinical trial planning and management. Pharmica ... patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were able ...
Breaking Medicine News(10 mins):